{"id":727559,"date":"2023-02-01T07:06:40","date_gmt":"2023-02-01T12:06:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/"},"modified":"2023-02-01T07:06:40","modified_gmt":"2023-02-01T12:06:40","slug":"immunocore-to-present-at-upcoming-investor-conferences-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/","title":{"rendered":"Immunocore to present at upcoming investor conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>Immunocore <\/strong><br \/>\n        <strong>to present at <\/strong><br \/>\n        <strong>upcoming investor conferences<\/strong>\n      <\/p>\n<p align=\"justify\">(OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Guggenheim Oncology Conference<\/strong><br \/>\n          <br \/>Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>SVB Securities Global Biopharma Conference<\/strong><br \/>\n          <br \/>Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Citi&#8217;s 2023 Virtual Oncology Leadership Summit<\/strong><br \/>\n          <br \/>Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET<\/li>\n<\/ul>\n<p align=\"justify\">The presentations will be webcast live and will be available in the \u2018Investors\u2019 section of Immunocore\u2019s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.<\/p>\n<p align=\"center\">##<\/p>\n<p align=\"justify\">\n        <strong>About Immunocore<\/strong>\n      <\/p>\n<p>Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX \u2013 Immune mobilizing monoclonal TCRs Against X disease \u2013 designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company\u2019s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\u00a0<\/p>\n<p>\n        <strong>Immunocore <\/strong><br \/>\n        <br \/>S\u00e9bastien Desprez, Head of Communications<br \/>T: +44 (0) 7458030732<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k1eL5utWNBXdgz9SUo8ghLxPZa971RuARbYhoJ2-V1qUGZUbVFZU2ANiiGXP5uvUXgNAqhRGSytbLSPTWKLB-L2Fd8FwdBq9eu43ji9liK7d1G29n7ZOFKKWkyZwRWhg\" rel=\"nofollow noopener\" target=\"_blank\">sebastien.desprez@immunocore.com<\/a><br \/>Follow on Twitter: @Immunocore<\/p>\n<p>\n        <strong>Consilium<\/strong><br \/>\n        <strong> Strategic Communications (corporate and financial)<\/strong><br \/>\n        <br \/>Mary-Jane Elliott\/ Chris Welsh\/Jessica Hodgson<br \/>T: +44 (0)203 709 5700<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UQeqXIv4g-iYJ8Ul4WS8boGe7PFO30EfmY0T6BOjQAunoFQNZRpG90MJEaoBgd2i0XjxTypwTzj3trhzEMw4HuHUw5xwZ60cEk2bCipVUrIxmb54JyrTAjoiPdwUKfYq\" rel=\"nofollow noopener\" target=\"_blank\">Immunocore@consilium-comms.com<\/a><\/p>\n<p>\n        <strong>Investor Relations \u00a0<\/strong><br \/>\n        <br \/>Clayton Robertson, Head of Investor Relations<br \/>T: +1 215-384-4781<br \/>E: ir@immunocore.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YmRkNDgwNWQtOWFkOS00N2JiLThhMWQtZWNkODAwZWFkYWEwLTEyMTc4MTE=\/tiny\/Immunocore-Holdings-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February: Guggenheim Oncology Conference Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET SVB Securities Global Biopharma Conference Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET Citi&#8217;s 2023 Virtual Oncology Leadership Summit Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET The presentations will be webcast live and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunocore to present at upcoming investor conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727559","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunocore to present at upcoming investor conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunocore to present at upcoming investor conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February: Guggenheim Oncology Conference Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET SVB Securities Global Biopharma Conference Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET Citi&#8217;s 2023 Virtual Oncology Leadership Summit Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET The presentations will be webcast live and &hellip; Continue reading &quot;Immunocore to present at upcoming investor conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T12:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunocore to present at upcoming investor conferences\",\"datePublished\":\"2023-02-01T12:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/\",\"name\":\"Immunocore to present at upcoming investor conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\",\"datePublished\":\"2023-02-01T12:06:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunocore-to-present-at-upcoming-investor-conferences-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunocore to present at upcoming investor conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunocore to present at upcoming investor conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/","og_locale":"en_US","og_type":"article","og_title":"Immunocore to present at upcoming investor conferences - Market Newsdesk","og_description":"Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February: Guggenheim Oncology Conference Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET SVB Securities Global Biopharma Conference Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET Citi&#8217;s 2023 Virtual Oncology Leadership Summit Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET The presentations will be webcast live and &hellip; Continue reading \"Immunocore to present at upcoming investor conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T12:06:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunocore to present at upcoming investor conferences","datePublished":"2023-02-01T12:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/","name":"Immunocore to present at upcoming investor conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==","datePublished":"2023-02-01T12:06:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc4MDA2NiM0MDE0NzY0MjQjMjIwNjI1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-to-present-at-upcoming-investor-conferences-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunocore to present at upcoming investor conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727559"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727559\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}